Tonix Pharmaceuticals Holding Corp. - FORM 10-K - EX-23.01 - CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM - March 15, 2021

Attached files

file filename
EX-31.02 - CERTIFICATION OF CHIEF FINANCIAL OFFICER - Tonix Pharmaceuticals Holding Corp.ex31-02.htm
10-K - ANNUAL REPORT - Tonix Pharmaceuticals Holding Corp.tnxp-10k_123120.htm
EX-32.01 - CERTIFICATIONS OF CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER - Tonix Pharmaceuticals Holding Corp.ex32-01.htm
EX-31.01 - CRERTIFICATION OF CHIEF EXECUTIVE OFFICER - Tonix Pharmaceuticals Holding Corp.ex31-01.htm
EX-21.01 - SUBSIDIARIES OF THE COMPANY - Tonix Pharmaceuticals Holding Corp.ex21-1.htm
EX-10.28 - PURCHASE AND SALE AGREEMENT - Tonix Pharmaceuticals Holding Corp.ex10-28.htm
EX-4.06 - DESCRIPTION OF REGISTRANTS SECURITIES - Tonix Pharmaceuticals Holding Corp.ex4-06.htm

 

Tonix Pharmaceuticals, Inc. 10-K

 

Exhibit 23.01

 

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 

We consent to the incorporation by reference in the Registration Statements of Tonix Pharmaceuticals Holding Corp. on Form S-1 (Nos. 333-234263, 333-235976) Form S-3 (Nos. 333-224586, 333-251500, 333-237610) and Form S-8 (Nos. 333-202006, 333-212300, 333-219928, 333-226776, 333-232137, and 333-239152) of our report dated March 15, 2021, on our audit of the consolidated financial statements as of December 31, 2020 and 2019 and for each of the years then ended, which report is included in this Annual Report on Form 10-K. Our report includes an explanatory paragraph about the existence of substantial doubt concerning the Company's ability to continue as a going concern.

 

/s/ EisnerAmper LLP

 

EISNERAMPER LLP

Iselin, New Jersey 

March 15, 2021

 

 

Tonix Pharmaceuticals Holding Corp. Reports